Unleashing the Power of γδ-T Cells with REAlease Technology

γδ-T cells represent a unique subset of immune cells that share characteristics of the innate and adaptive immune system. They are not MHC-restricted, making them promising candidates for allogeneic CAR T cell therapies. Enrichment of γδ T cells allows to simplify research, improve understanding of their biology and facilitate developments for therapeutic applications. The cutting-edge REAlease technology offers a direct means of enriching unlabeled cells from diverse blood materials. The option of full automation contributes to the standardization of routine separations, concurrently minimizing hands-on time. Evaluation of separation performance and functionality was conducted through flow cytometric analyses and in-vitro assays. Demonstrating the utility of the newly developed REAlease γδ T-cell MicroBead Kits, we achieved high-purity enrichment from PBMC, BC, WB and leukopak. The ratio of γδ T subtypes in enriched fractions was analyzed,, as well as the activation status. Isolated cells showed no expression of activation marker CD69 and remained inactive in culture. Stimulation effectively activated the cells showcasing their full functionality. Subsequent analysis examined cytokine secretion in non-stimulated and stimulated cells. The isolation strategy presented minimizes cell manipulation and reduces interference with downstream processes. It can thus make an important contribution to the progress of disease research and the exploration of new therapeutic possibilities.